Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will host its third quarter 2020 investor update conference call on November 5, 2020, at 4:30 p.m. Eastern Time. Participants can dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) to join the call using conference ID 2794527. A replay will be available starting the same day at 7:30 p.m. ET through November 19 at (800) 585-8367 (U.S. and Canada). Ironwood is focused on developing therapies for gastrointestinal diseases, notably linaclotide for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced disappointing results from its Phase III trial IW-3718-302 for IW-3718, which failed to meet primary endpoints for treating refractory gastroesophageal reflux disease (GERD). Following this, Ironwood will discontinue IW-3718's development and halt enrollment in another related trial. The company plans to reduce its workforce by 35%, saving over $95 million, but incur one-time costs of up to $12 million linked to the layoffs. Ironwood remains focused on maximizing LINZESS, its leading GI medication.